This is the new fantasy creature from the Phantasticals campaign that Ferrer has relaunched, coinciding with Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, on June 21. The aim is to raise public awareness of this rare, neurodegenerative, progressive disease that affects the motor neurons in the brain. Ferrer is leading the ADORE Phase III clinical trial to evaluate the safety and efficacy of the investigational drug FNP122 in the treatment of ALS.
Read MoreBrazil biomedical warming and thawing devices market is expected to expand at a CAGR of 8.4% through 2027 led by the rising incidence of accidental injuries across the country.
Read MoreThe Pharmacovigilance 2010 a first of its kinds congruence of the leaders from Pharmacovigilance domain in India, recently concluded in Mumbai which was well attended by the thought leaders from and had the top strata of the industry participating.
Read More